NFKB1 and fatty liver disease: The activation of the IKKβ/NF-κB pathway has been shown to promote fatty liver disease, or hepatic steatosis (91), whereas inhibition of IKKβ prevents the initiation of steatosis and non-alcoholic steatohepatitis (75, 92).